Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Banco de datos
Tipo del documento
Asunto de la revista
Intervalo de año de publicación
1.
Blood ; 140(1): 38-44, 2022 07 07.
Artículo en Inglés | MEDLINE | ID: mdl-35421218

RESUMEN

CD19-directed immunotherapies have revolutionized the treatment of advanced B-cell acute lymphoblastic leukemia (B-ALL). Despite initial impressive rates of complete remission (CR) many patients ultimately relapse. Patients with B-ALL successfully treated with CD19-directed T cells eventually relapse, which, coupled with the early onset of CD22 expression during B-cell development, suggests that preexisting CD34+CD22+CD19- (pre)-leukemic cells represent an "early progenitor origin-related" mechanism underlying phenotypic escape to CD19-directed immunotherapies. We demonstrate that CD22 expression precedes CD19 expression during B-cell development. CD34+CD19-CD22+ cells are found in diagnostic and relapsed bone marrow samples of ∼70% of patients with B-ALL, and their frequency increases twofold in patients with B-ALL in CR after CD19 CAR T-cell therapy. The median of CD34+CD19-CD22+ cells before treatment was threefold higher in patients in whom B-ALL relapsed after CD19-directed immunotherapy (median follow-up, 24 months). Fluorescence in situ hybridization analysis in flow-sorted cell populations and xenograft modeling revealed that CD34+CD19-CD22+ cells harbor the genetic abnormalities present at diagnosis and initiate leukemogenesis in vivo. Our data suggest that preleukemic CD34+CD19-CD22+ progenitors underlie phenotypic escape after CD19-directed immunotherapies and reinforce ongoing clinical studies aimed at CD19/CD22 dual targeting as a strategy for reducing CD19- relapses. The implementation of CD34/CD19/CD22 immunophenotyping in clinical laboratories for initial diagnosis and subsequent monitoring of patients with B-ALL during CD19-targeted therapy is encouraged.


Asunto(s)
Antígenos CD19 , Linfoma de Burkitt , Antígenos CD34 , Linfocitos B , Humanos , Inmunofenotipificación , Hibridación Fluorescente in Situ , Recurrencia , Lectina 2 Similar a Ig de Unión al Ácido Siálico
2.
Nat Commun ; 12(1): 821, 2021 02 05.
Artículo en Inglés | MEDLINE | ID: mdl-33547282

RESUMEN

Down syndrome is associated with genome-wide perturbation of gene expression, which may be mediated by epigenetic changes. We perform an epigenome-wide association study on neonatal bloodspots comparing 196 newborns with Down syndrome and 439 newborns without Down syndrome, adjusting for cell-type heterogeneity, which identifies 652 epigenome-wide significant CpGs (P < 7.67 × 10-8) and 1,052 differentially methylated regions. Differential methylation at promoter/enhancer regions correlates with gene expression changes in Down syndrome versus non-Down syndrome fetal liver hematopoietic stem/progenitor cells (P < 0.0001). The top two differentially methylated regions overlap RUNX1 and FLI1, both important regulators of megakaryopoiesis and hematopoietic development, with significant hypermethylation at promoter regions of these two genes. Excluding Down syndrome newborns harboring preleukemic GATA1 mutations (N = 30), identified by targeted sequencing, has minimal impact on the epigenome-wide association study results. Down syndrome has profound, genome-wide effects on DNA methylation in hematopoietic cells in early life, which may contribute to the high frequency of hematological problems, including leukemia, in children with Down syndrome.


Asunto(s)
Subunidad alfa 2 del Factor de Unión al Sitio Principal/genética , Síndrome de Down/genética , Epigénesis Genética , Hematopoyesis/genética , Células Madre Hematopoyéticas/metabolismo , Proteína Proto-Oncogénica c-fli-1/genética , Estudios de Casos y Controles , Subunidad alfa 2 del Factor de Unión al Sitio Principal/metabolismo , Islas de CpG , Metilación de ADN , Síndrome de Down/metabolismo , Síndrome de Down/patología , Femenino , Feto , Factor de Transcripción GATA1/genética , Factor de Transcripción GATA1/metabolismo , Genoma Humano , Estudio de Asociación del Genoma Completo , Células Madre Hematopoyéticas/patología , Humanos , Recién Nacido , Hígado/metabolismo , Hígado/patología , Masculino , Regiones Promotoras Genéticas , Proteína Proto-Oncogénica c-fli-1/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA